Medifacts International Drives Innovation In Telemedicine For Clinical Trials

Main Category: Clinical Trials / Drug Trials
Also Included In: IT / Internet / E-mail
Article Date: 17 Dec 2009 - 9:00 PDT

email to a friend   printer friendly   opinions  

Medifacts International, Inc., one of the largest global providers of noninvasive cardiovascular diagnostic services, announced that they are once again leading the Cardiovascular Safety Services marketplace in innovation, expertise, and execution - this time with new innovations in the use of telemedicine, T-SMBP (Telemonitoring Self Measured Blood Pressure), in clinical trials.

T-SMBP allows for remote collection of blood pressure (BP) data from a subject's home. Telemonitoring and telemedicine are actively being implemented through health care providers for general patient care, specifically in patients being treated for heart failure, diabetes, cancer and hypertension. The transition and implementation of telemedicine in clinical trials provides many benefits to the conduct of the study. The benefits of implementing T-SMBP include: (i) electronic capture of BP data, which removes transcription errors; (ii) reduction in the number of office visits required by the subject; and perhaps most importantly (iii) real-time access to the subjects' BP data via study web portal, which allows for alert criteria process and real-time view of data trends and treatment effect.

Over the past two years, Medifacts has worked with their partners and devoted key resources to advancing the design, implementation and execution of T-SMBP in clinical trials to enhance a solution that is both functional and cost-effective. As the global leader in ABPM (Ambulatory Blood Pressure Monitoring), Medifacts was able to access its vast reservoir of real-time clinical trial ABPM experience to enhance its T-SMBP solution.

Medifacts will present best practices and case studies of effective implementation of T-SMBP in clinical trials at The Med-e-Tel 2010 Conference in Luxembourg, April 14-16, 2010.

Michael Woehler, Medifacts International's President and Chief Executive Officer said: "We are seeing a very positive reaction to our proactive approach regarding technologies, study designs and timetables. It's important to our clients that we be innovative and driven toward more effective solutions. Our commitment to serve our clients' needs continues to pay dividends as we advance our position as one of the top global companies providing cardiovascular safety solutions."

Source
Medifacts International, Inc.

• Additional
• References
• Citations